All In Biotech

Drug Trial Radar · NCT05794659

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

A Randomized Phase 2 Study to Evaluate the Efficacy and Safety for Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer (Cornerstone-004)

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Jun 1, 2027

Primary completion

Dec 31, 2030

Study completion Jun 1, 2031

Sponsor

Lead sponsor
Aston Sci. Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 2 study is to assess the efficacy and safety for adjuvant therapeutic cancer vaccine AST-201 (pUMVC3-hIGFBP-2) in patients with newly diagnosed homologous-recombination proficient(HRP) advanced ovarian cancer (Stage III) after debulking surgery. Patients will receive AST-201 with rhuGM-CSF(Colony Stimulating Factor) or placebo with rhuGM-CSF in combination with standard adjuvant chemotherapy(Paclitaxel/Carboplatin).

Conditions

  • Advanced Ovarian Cancer

Interventions

  • AST-201Biological

    i.d. (3-week interval, 3 cycles in total)

  • PaclitaxelDrug

    3-week interval, 6 cycles in total

  • CarboplatinDrug

    3-week interval, 6 cycles in total

  • PlaceboDrug

    i.d. (3-week interval, 3 cycles in total)

  • rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)Drug

    i.d. (3-week interval, 3 cycles in total)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: overall study duration (approximately 48 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Washington

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.